Concepedia

Publication | Closed Access

Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double‐blind, randomized, placebo‐controlled trial

DOI

82

Citations

8

References

2014

Year

Dominik Riss, Martin Burian, Axel Wolf, Veronika Kranebitter, Alexandra Kaider, Christoph Arnoldner
Head & Neck

Abstract

Results show a trend toward reduced epistaxis with bevacizumab. This further supports the use of bevacizumab in HHT. Clincial Trials. gov number: NCT01314274

References

YearCitations

Page 1